半胱氨酰白三烯受体拮抗剂在心血管疾病中的研究进展  

Research progress of cysteinyl leukotriene receptor antagonist in cardiovascular disease

作　　者：周洁[1] 黄星原[1] 魏丽[1] 刘奥杰[1] 张婧[1] 陈娇娇[1] 

机构地区：[1]武汉大学人民医院,湖北武汉430060

出　　处：《职业与健康》2017年第4期569-572,共4页Occupation and Health

摘　　要：炎症是影响各种心血管疾病严重程度以及慢性期恢复的主要因素之一,半胱氨酰白三烯(Cys LTs)是参与炎性疾病中的强力致痉和免疫调节脂质的炎症介质,由花生四烯酸(AA)经脂质氧化酶通路生成,通过半胱氨酰白三烯受体(Cys LT1R和Cys LT2R)调节心血管疾病后炎症等病变。目前,研究已证实半胱氨酰白三烯受体拮抗剂(Cys LTRs拮抗剂)在动脉粥样硬化、川崎病、肺心病及心肌缺血再灌注损伤中的保护作用,本文就作用机制及其在心血管疾病中的临床研究进展综述如下。Inflammation is one of the factors affecting severity and recovery of chronic phase of various cardiovascular disease.Cysteinyl leukotrienes（Cys LTs） is strongly involved in inflammatory diseases and immune regulation of spasm induced by lipid mediators of inflammation. It is generated in enzyme pathway of arachidonic acid（AA）lipid oxidation,and regulates inflammatory after vascular disease through incysteinyl leukotriene receptors（Cys LT1 R and Cys LT2R）. Presently,studies have identified Cys LTs antagonist plays protective role in atherosclerosis,Kawasaki disease,Corpulmonale and myocardial ischemia-reperfusion injury.This paper summarizes the mechanism of action of Cys LTs antagonist in cardiovascular disease and its progress on clinical research.

关 键 词：半胱氨酰白三烯受体拮抗剂 心血管疾病 炎症 

分 类 号：R54[医药卫生—心血管疾病]